Skip to main content

Table 1 Baseline characteristics of patients included in the study

From: Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial

  Active ILIT Placebo ILIT
Number of participants 21 15
Age (y), median (range) 30 (20–52) 30 (20–54)
Gender (male vs. female) 13:8 9:6
Allergen-specific IgE (kU/L) 4.4 – 100.0 0.47 – 78.6
Birch vs. grass vaccination 8:13 6:8